MedPath

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Phase 2
Active, not recruiting
Conditions
Non-alcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
NAFLD
Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis
Interventions
Registration Number
NCT05877547
Lead Sponsor
Merck Sharp & Dohme LLC
Brief Summary

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
360
Inclusion Criteria
  • Histological confirmation of NASH, defined as NAFLD Activity Score (NAS) ≥4 with a score ≥1 point in each component (steatosis, ballooning, and lobular inflammation) AND NASH clinical research network (CRN) fibrosis score of Stage 2 or 3
  • No history of Type 2 diabetes mellitus (T2DM) OR a history of T2DM with an A1C ≤9% that is controlled by diet or stable doses of antihyperglycemic agents (AHAs)
  • Participants in South Korea are eligible between the ages of 19 to 80 years of age (inclusive)
Exclusion Criteria
  • History of liver disease other than NASH
  • History or evidence of cirrhosis
  • History of pancreatitis
  • History of Type 1 diabetes mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatectomy
  • History of a bariatric surgical procedure ≤5 years before study entry, or a known clinically significant gastric emptying abnormality
  • Has significant systemic or major illnesses, including recent events (≤6 months before study entry) of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or transient ischemic attack

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo administered by SC injection once weekly for 52 weeks
Efinopegdutide 7mgEfinopegdutideEfinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, and 7 mg for 44 weeks.
Efinopegdutide 10mgEfinopegdutideEfinopegdutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks, 4 mg for 4 weeks, 7 mg for 4 weeks, and 10 mg for 40 weeks.
Semaglutide 2.4 mgSemaglutideSemaglutide administered by SC injection once weekly for 52 weeks in a dose-escalation regimen of 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, and 2.4 mg for 36 weeks.
Efinopegdutide 4mgEfinopegdutideEfinopegdutide administered by subcutaneous (SC) injection once weekly for 52 weeks in a dose-escalation regimen of 2 mg for 4 weeks and 4mg for 48 weeks.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis At Week 52Week 52

The NASH Clinical Research Network (CRN) scoring system evaluated by Blinded Independent Central Review (BICR) is used to assess treatment response. The NASH CRN scoring scales are: lobular inflammation score (0-3); hepatocyte ballooning score (0-2); steatosis score (0-3); and fibrosis score (0-4). NASH resolution is defined as a score of 0-1 for inflammation, 0 for ballooning, and any grade of steatosis.

Percentage of Participants Who Experienced an Adverse Event (AE)Up to 60 weeks

An adverse event (AE) is a health problem that happens or worsens during a study.

Percentage of Participants Discontinuing Study Medication Due to an AEUp to 52 weeks

An adverse event (AE) is a health problem that happens or worsens during a study.

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis At Week 52Week 52

Participants will be assessed using the NASH CRN scoring system evaluated by BICR for ≥1-stage improvement in fibrosis without worsening of steatohepatitis. Fibrosis is scored from stage 0 to 4 where 0 = None, 1=Perisinusoidal OR periportal, 2=Perisinusoidal AND portal/periportal, 3= Bridging fibrosis, 4=Cirrhosis. No worsening of steatohepatitis is defined as no increase in the ballooning, inflammation, or steatosis scores.

Change from Baseline in Body Weight At Week 52Week 52

Body weight (kg) will be measured using a standardized, digital scale. The percent change from baseline in body weight after 52 weeks will be reported.

Trial Locations

Locations (175)

Indago Research & Health Center, Inc ( Site 3207)

🇺🇸

Hialeah, Florida, United States

Sweet Hope Research Specialty, Inc-Research ( Site 3200)

🇺🇸

Hialeah, Florida, United States

Velocity Clinical Research, Syracuse ( Site 3227)

🇺🇸

East Syracuse, New York, United States

Singapore General Hospital ( Site 2188)

🇸🇬

Singapore, Central Singapore, Singapore

Eagle Clinical Research ( Site 3233)

🇺🇸

Chicago, Illinois, United States

Houston Research Institute ( Site 3262)

🇺🇸

Houston, Texas, United States

Genoma Research Group ( Site 3242)

🇺🇸

Miami, Florida, United States

The Machuca Foundation ( Site 3234)

🇺🇸

Las Vegas, Nevada, United States

Velocity Clinical Research, Cincinnati ( Site 3237)

🇺🇸

Cincinnati, Ohio, United States

American Research Corporation ( Site 3202)

🇺🇸

San Antonio, Texas, United States

Pinnacle Clinical Research ( Site 3284)

🇺🇸

San Antonio, Texas, United States

Om Research - Apple Valley ( Site 3244)

🇺🇸

Apple Valley, California, United States

Barzilai Medical Center ( Site 1306)

🇮🇱

Ashkelon, Israel

Hospital Universitario "Dr. Jose Eleuterio Gonzalez" ( Site 1604)

🇲🇽

Monterrey, Nuevo Leon, Mexico

Unidade Local de Saúde do Alto Ave - Hospital Senhora da Oliveira ( Site 1905)

🇵🇹

Guimaraes, Braga, Portugal

Unidade Local de Saude Lisboa Ocidental - Hospital Egas Moniz ( Site 1906)

🇵🇹

Lisbon, Lisboa, Portugal

Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 1904)

🇵🇹

Lisbon, Lisboa, Portugal

St James's University Hospital ( Site 3005)

🇬🇧

Leeds, United Kingdom

The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3

🇺🇸

Chandler, Arizona, United States

The Institute for Liver Health II dba Arizona Clinical Trials - Peoria ( Site 3289)

🇺🇸

Peoria, Arizona, United States

The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 3218)

🇺🇸

Tucson, Arizona, United States

Del Sol Research Management, LLC ( Site 3211)

🇺🇸

Tucson, Arizona, United States

Om Research LLC ( Site 3245)

🇺🇸

Camarillo, California, United States

Velocity Clinical Research, Gardena ( Site 3225)

🇺🇸

Gardena, California, United States

Velocity Clinical Research, Huntington Park ( Site 3217)

🇺🇸

Huntington Park, California, United States

Velocity Clinical Research, San Diego ( Site 3226)

🇺🇸

La Mesa, California, United States

Om Research LLC ( Site 3229)

🇺🇸

Lancaster, California, United States

Velocity Clinical Research, Westlake ( Site 3216)

🇺🇸

Los Angeles, California, United States

California Liver Research Institute ( Site 3232)

🇺🇸

Pasadena, California, United States

Velocity Clinical Research, Panorama City ( Site 3214)

🇺🇸

Panorama City, California, United States

Excel Medical Clinical Trials ( Site 3246)

🇺🇸

Boca Raton, Florida, United States

Synergy Healthcare ( Site 3286)

🇺🇸

Bradenton, Florida, United States

Synergy Healthcare LLC ( Site 3290)

🇺🇸

Brandon, Florida, United States

Top Medical Research ( Site 3209)

🇺🇸

Cutler Bay, Florida, United States

Covenant Metabolic Specialists, LLC ( Site 3231)

🇺🇸

Fort Myers, Florida, United States

Velocity Clinical Research, Hallandale Beach ( Site 3241)

🇺🇸

Hallandale Beach, Florida, United States

Floridian Clinical Research, LLC ( Site 3203)

🇺🇸

Miami Lakes, Florida, United States

University of Iowa ( Site 3213)

🇺🇸

Iowa City, Iowa, United States

Southeast Clinical Research Center ( Site 3288)

🇺🇸

Dalton, Georgia, United States

Florida Research Institute ( Site 3243)

🇺🇸

Lakewood Ranch, Florida, United States

New York Gastroenterology Associates ( Site 3252)

🇺🇸

New York, New York, United States

Velocity Clinical Research, Dallas ( Site 3220)

🇺🇸

Dallas, Texas, United States

Velocity Clinical Research, Salt Lake City ( Site 3223)

🇺🇸

West Jordan, Utah, United States

Velocity Clinical Research, Providence ( Site 3222)

🇺🇸

East Greenwich, Rhode Island, United States

South Texas Research Institute - Brownsville ( Site 3285)

🇺🇸

Brownsville, Texas, United States

Gastroenterology Consultants of Southwest Virginia ( Site 3282)

🇺🇸

Roanoke, Virginia, United States

Antwerp University Hospital-Gastr-enterologie/hepatologie ( Site 3300)

🇧🇪

Edegem, Antwerpen, Belgium

Medizinische Universität Graz-Department of Internal Medicine ( Site 0302)

🇦🇹

Graz, Steiermark, Austria

AZ Maria Middelares-Digestief Centrum ( Site 3301)

🇧🇪

Gent, Oost-Vlaanderen, Belgium

Heritage Medical Research Clinic ( Site 0403)

🇨🇦

Calgary, Alberta, Canada

UZ Leuven-Hepatology ( Site 3302)

🇧🇪

Leuven, Vlaams-Brabant, Belgium

Toronto General Hospital ( Site 0402)

🇨🇦

Toronto, Ontario, Canada

Vancouver General Hospital-Gastroenterology ( Site 0408)

🇨🇦

Vancouver, British Columbia, Canada

McGill University Health Centre ( Site 0400)

🇨🇦

Montréal, Quebec, Canada

Diex Recherche Quebec Inc. ( Site 0409)

🇨🇦

Quebec, Canada

Enroll SpA ( Site 0501)

🇨🇱

Providencia, Region M. De Santiago, Chile

CECIM ( Site 0500)

🇨🇱

Santiago, Region M. De Santiago, Chile

Pontificia Universidad Catolica de Chile-CICUC ( Site 0502)

🇨🇱

Santiago, Region M. De Santiago, Chile

The First Affiliated Hospital, Sun Yat-sen University ( Site 0603)

🇨🇳

Guangzhou, Guangdong, China

Beijing Youan Hospital ( Site 0602)

🇨🇳

Beijing, Beijing, China

Beijing Tsinghua Changgung Hospital ( Site 0606)

🇨🇳

Beijing, Beijing, China

Chongqing University Three Gorges Hospital ( Site 0607)

🇨🇳

Wanzhou, Chongqing, China

Southern Medical University Nanfang Hospital ( Site 0601)

🇨🇳

Guangzhou, Guangdong, China

No. 2 Hospital of Nanjing ( Site 0605)

🇨🇳

Nanjing, Jiangsu, China

West China Hospital, Sichuan University ( Site 0611)

🇨🇳

Cheng Du, Sichuan, China

Tianjin Second People's Hospital ( Site 0604)

🇨🇳

Tianjin, Tianjin, China

Fundación Centro de Investigación Clínica CIC ( Site 0704)

🇨🇴

Medellín, Antioquia, Colombia

Sociedad De Oncología y Hematología Del Cesar SAS ( Site 0708)

🇨🇴

Valledupar, Cesar, Colombia

The First Affiliated Hospital of Wenzhou Medical University ( Site 0609)

🇨🇳

Wenzhou, Zhejiang, China

Oncomédica S.A.S ( Site 0702)

🇨🇴

Montería, Cordoba, Colombia

Fundacion Santa Fe de Bogota ( Site 0701)

🇨🇴

Bogotá, Cundinamarca, Colombia

Solano & Terront Servicios Medicos - UNIENDO ( Site 0705)

🇨🇴

Bogotá, Cundinamarca, Colombia

KlinMed ( Site 0801)

🇨🇿

Prague, Praha 2, Czechia

Krajská nemocnice Liberec ( Site 0800)

🇨🇿

Liberec, Czechia

Vseobecna fakultni nemocnice v Praze ( Site 0802)

🇨🇿

Praha 2, Czechia

CHU Charles Nicolle ( Site 0910)

🇫🇷

Rouen, Haute-Normandie, France

Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Pôle de Référence Hépato Gastro-entérol

🇫🇷

Nice, Alpes-Maritimes, France

Hôpital Beaujon-Hépatologie ( Site 0908)

🇫🇷

Clichy, Hauts-de-Seine, France

CHU Bordeaux Haut-Leveque-Service d'Hépato-gastroentérologie ( Site 0904)

🇫🇷

Pessac, Aquitaine, France

Centre Hospitalier Universitaire d'Angers-Hepato Gastroenterology ( Site 0900)

🇫🇷

Angers, Maine-et-Loire, France

Hôpital Saint Antoine ( Site 0914)

🇫🇷

Paris, France

Hopitaux Universitaires Paris Centre-Hopital Cochin-Service HEPATOLOGIE- Recherche Clinique ( Site 0

🇫🇷

Paris, France

Centre Hospitalier Universitaire Estaing ( Site 0913)

🇫🇷

Clermont-Ferrand, Puy-de-Dome, France

Hôpital de la Croix Rousse-Centre de Recherche Clinique ( Site 0911)

🇫🇷

Lyon, Rhone-Alpes, France

centre hospitalier lyon sud-Endocrinologie, Diabète et Nutrition ( Site 0906)

🇫🇷

Pierre-Bénite, Rhone-Alpes, France

SYNEXUS Magyarország Kft. Eü. ( Site 1110)

🇭🇺

Budapest, Hungary

Dél-Pesti Centrumkórház-Hepatologiai Szakrendekő ( Site 1102)

🇭🇺

Budapest, Hungary

Rambam Health Care Campus ( Site 1304)

🇮🇱

Haifa, Israel

Carmel Hospital ( Site 1305)

🇮🇱

Haifa, Israel

Shaare Zedek Medical Center-Liver Unit ( Site 1302)

🇮🇱

Jerusalem, Israel

Rabin Medical Center ( Site 1301)

🇮🇱

Petah Tikva, Israel

Sheba Medical Center ( Site 1300)

🇮🇱

Ramat Gan, Israel

Maccabi Health Services - Ramat Hasharon ( Site 1303)

🇮🇱

Ramat Hasharon, Israel

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Dipartimento di Medicina Interna e Gas

🇮🇹

Roma, Lazio, Italy

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 1403)

🇮🇹

Milano, Lombardia, Italy

Humanitas-Medicina interna ed Epatologia ( Site 1400)

🇮🇹

Rozzano, Lombardia, Italy

A.O.U. Policlinico Paolo Giaccone-Dep. Of Internal Medicine and Specialistic ( Site 1402)

🇮🇹

Palermo, Sicilia, Italy

Azienda Ospedaliero-Universitaria Città della Salute e della-S.C. Gastroenterologia U. ( Site 1401)

🇮🇹

Torino, Italy

Ehime University Hospital ( Site 1509)

🇯🇵

Toon, Ehime, Japan

Kurume University Hospital ( Site 1504)

🇯🇵

Kurume, Fukuoka, Japan

Ogaki Municipal Hospital ( Site 1511)

🇯🇵

Ogaki, Gifu, Japan

Kagawa University Hospital ( Site 1515)

🇯🇵

Kita, Kagawa, Japan

Toranomon Hospital Kajigaya ( Site 1502)

🇯🇵

Kawasaki, Kanagawa, Japan

Sapporo Kosei General Hospital ( Site 1521)

🇯🇵

Sapporo, Hokkaido, Japan

Kagawa Prefectural Central Hospital ( Site 1514)

🇯🇵

Takamatsu, Kagawa, Japan

Nara Medical University Hospital ( Site 1513)

🇯🇵

Kashihara, Nara, Japan

Shinyurigaoka General Hospital ( Site 1518)

🇯🇵

Kawasaki, Kanagawa, Japan

St. Marianna University Hospital ( Site 1516)

🇯🇵

Kawasaki, Kanagawa, Japan

Yokohama City University Hospital ( Site 1505)

🇯🇵

Yokohama, Kanagawa, Japan

Shinshu University Hospital ( Site 1512)

🇯🇵

Matsumoto, Nagano, Japan

Toranomon Hospital ( Site 1501)

🇯🇵

Minato-ku, Tokyo, Japan

Osaka Saiseikai Suita Hospital ( Site 1503)

🇯🇵

Suita, Osaka, Japan

Fukuiken Saiseikai Hospital ( Site 1507)

🇯🇵

Fukui, Japan

Gifu Municipal Hospital ( Site 1506)

🇯🇵

Gifu, Japan

University Hospital,Kyoto Prefectural University of Medicine ( Site 1519)

🇯🇵

Kyoto, Japan

Kawasaki Medical School General Medical Center ( Site 1508)

🇯🇵

Okayama, Japan

Osaka Metropolitan University Hospital ( Site 1520)

🇯🇵

Osaka, Japan

Saga University Hospital ( Site 1510)

🇯🇵

Saga, Japan

Japanese Red Cross Musashino Hospital ( Site 1517)

🇯🇵

Tokyo, Japan

Boramae Medical Center-Internal Medicine ( Site 2403)

🇰🇷

Dongjak-gu, Seoul, Korea, Republic of

Inha University Hospital-Gastroenterolgy/Hepatology ( Site 2402)

🇰🇷

Incheon, Korea, Republic of

Medica Sur-Clinica de Enfermedades Digestivas y Obesidad ( Site 1603)

🇲🇽

Mexico City, Distrito Federal, Mexico

Samsung Medical Center-Gastroenterology/Internal Medicine ( Site 2400)

🇰🇷

Seoul, Korea, Republic of

Servicios de Oncología Médica Integral - Monterrey ( Site 1611)

🇲🇽

Monterrey, Nuevo Leon, Mexico

ICARO Investigaciones en Medicina ( Site 1608)

🇲🇽

Chihuahua, Mexico

Centro de investigacion Clínica Trujillo ( Site 1802)

🇵🇪

Trujillo, La Libertad, Peru

Centro de Investigación y Gastroenterología - S.C. ( Site 1609)

🇲🇽

Mexico City, Mexico

Oaxaca Site Management Organization ( Site 1613)

🇲🇽

Oaxaca, Mexico

Centro de Investigacion Clinica de Oaxaca ( Site 1607)

🇲🇽

Oaxaca, Mexico

CLINICA DELGADO-Clinical Research ( Site 1800)

🇵🇪

Miraflores, Lima, Peru

Centro de Investigación y Gastroenterología ( Site 1601)

🇲🇽

Cuauhtemoc, Mexico

Instituto Médico Soy Diabetico ( Site 1804)

🇵🇪

Piura, Peru

ULSAM - Hospital de Santa Luzia ( Site 1907)

🇵🇹

Viana do Castelo, Portugal

ISIS CLINICAL RESEARCH CENTER ( Site 2006)

🇵🇷

Guaynabo, Puerto Rico

Pan American Center for Oncology Trials ( Site 2000)

🇵🇷

Rio Piedras, Puerto Rico

Klinical Investigations Group-Clinical Research ( Site 2001)

🇵🇷

San Juan, Puerto Rico

Latin Clinical Trial Center ( Site 2004)

🇵🇷

San Juan, Puerto Rico

Hospital Universitario Marqués de Valdecilla-Gastroenterology and Hepatology ( Site 2505)

🇪🇸

Santander, Cantabria, Spain

Hospital General de Tomelloso-Aparato Digestivo ( Site 2514)

🇪🇸

Tomelloso, Ciudad Real, Spain

Hospital Universitario Virgen de la Victoria-UGC Endocrinologia y nutricion ( Site 2506)

🇪🇸

Malaga, Andalucia, Spain

CHUAC-Complejo Hospitalario Universitario A Coruña-Endocrinología ( Site 2511)

🇪🇸

A Coruña, La Coruna, Spain

Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 2507)

🇪🇸

Barcelona, Spain

CHUS - Hospital Clinico Universitario ( Site 2503)

🇪🇸

Santiago de Compostela, La Coruna, Spain

Hospital Universitario Ramón y Cajal ( Site 2508)

🇪🇸

Madrid, Madrid, Comunidad De, Spain

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Unidad de Ensayos Clínicos de Aparato Digestivo ( Site 2504)

🇪🇸

Sevilla, Spain

Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie ( Site 2601)

🇨🇭

St.Gallen, Sankt Gallen, Switzerland

Hospital Universitario La Paz-HEPATOLOGIA ( Site 2509)

🇪🇸

Madrid, Spain

HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA-Gastroenterologia y Hepatologia ( Site 2500)

🇪🇸

Madrid, Spain

Fondazione Epatocentro Ticino ( Site 2602)

🇨🇭

Lugano, Ticino, Switzerland

UniversitätsSpital Zürich-Gastroenterologie & Hepatologie ( Site 2603)

🇨🇭

Zürich, Zurich, Switzerland

Changhua Christian Hospital-Endocrinology and metabolism ( Site 2704)

🇨🇳

Changhua County, Changhua, Taiwan

Chiayi Christian Hospital ( Site 2707)

🇨🇳

Chiayi City, Chiayi, Taiwan

Taichung Veterans General Hospital ( Site 2703)

🇨🇳

Taichung, Taiwan

National Cheng Kung University Hospital-Liver Research team of National Cheng Kung University Hospi

🇨🇳

Tainan, Taiwan

National Taiwan University Hospital-Internal Medicine ( Site 2700)

🇨🇳

Taipei, Taiwan

Taipei Veterans General Hospital-Division of Gastroenterology & Hepatology, Department of Medicine (

🇨🇳

Taipei, Taiwan

Chang Gung Medical Foundation-Linkou Branch ( Site 2702)

🇨🇳

Taoyuan, Taiwan

Maharaj Nakorn Chiang Mai Hospital ( Site 2801)

🇹🇭

Muang, Chiang Mai, Thailand

Chulalongkorn University ( Site 2800)

🇹🇭

Bangkok, Krung Thep Maha Nakhon, Thailand

Royal London Hospital ( Site 3003)

🇬🇧

London, England, United Kingdom

Dokuz Eylul Universitesi Hastanesi-Gastroenterology ( Site 2905)

🇹🇷

İzmir, Turkey

Faculty of Medicine Siriraj Hospital-Department of Medicine ( Site 2802)

🇹🇭

Bangkok, Krung Thep Maha Nakhon, Thailand

Hacettepe Universite Hastaneleri-internal diseases ( Site 2901)

🇹🇷

Ankara, Turkey

Bezmialem Vakf Üniversitesi-Gastroenterology ( Site 2903)

🇹🇷

Istanbul, Turkey

T.C. Sağlik Bakanliği- Marmara Üniversitesi İstanbul Pendik -T.C. Sağlik Bakanliği- Marmara Ünivers

🇹🇷

Istanbul, Turkey

Recep Tayyip Erdogan University Training and Research Hospital ( Site 2900)

🇹🇷

Rize, Turkey

King's College Hospital ( Site 3002)

🇬🇧

London, London, City Of, United Kingdom

Aberdeen Royal Infirmary-Department of Gastroenterology ( Site 3004)

🇬🇧

Aberdeen, Scotland, United Kingdom

Queen Elizabeth Hospital Birmingham ( Site 3000)

🇬🇧

Birmingham, Warwickshire, United Kingdom

Severance Hospital, Yonsei University Health System ( Site 2401)

🇰🇷

Seoul, Korea, Republic of

Clinical Trials Research ( Site 3230)

🇺🇸

Sacramento, California, United States

Kansas City Research Institute ( Site 3249)

🇺🇸

Kansas City, Missouri, United States

Velocity Clinical Research, Austin ( Site 3235)

🇺🇸

Austin, Texas, United States

Fundación Valle del Lili ( Site 0700)

🇨🇴

Cali, Valle Del Cauca, Colombia

Prince of Wales Hospital ( Site 1000)

🇭🇰

Shatin, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath